Endovascular Engineering, E2, reports that it has received $42m in Series B funding to advance its next-generation clot removal technology platform for venous thromboembolism (VTE). The round was led by 415 Capital and S3 Ventures, with participation from Italian VC Panakes Partners, M&L Healthcare and support from founding investor Santé Ventures.
The capital injection accelerates Menlo Park, California-based E2’s mission to transform the treatment of VTE, focusing initially on advancing innovative solutions to address pulmonary embolism (PE). As the company nears completion of enrolment in the pivotal ENGULF study evaluating the Hēlo PE thrombectomy system, the additional capital strengthens E2’s position to address critical unmet needs in interventional medicine while pursuing a new standard of care for patients and physicians.
“This funding represents much more than capital: it validates our technology platform and positions us to revolutionise the treatment of PE,” says Dan Rose, CEO of E2 in a note. “With the strong backing of sophisticated healthcare investors such as 415 Capital and S3 Ventures, we are well positioned to establish the Hēlo PE system as the gold standard in mechanical thrombectomy for pulmonary embolism.
“E2 is developing a first-in-class therapy for PE, the third leading cause of cardiovascular death. Its differentiated technology and vision align closely with our mission to advance novel cardiovascular therapies, and we are proud to support E2 in its journey to advance the Hēlo PE thrombectomy platform towards FDA approval,” says Ruben Osnabrugge, partner at 415 Capital.
Brian R. Smith, CEO of S3 Ventures, adds: “We are very impressed with E2’s next-generation venereal thrombectomy platform technology and see it as a solution that can dramatically scale the mechanical thrombectomy market and improve patients’ lives.
The company also announced the appointment of Ruben Osnabrugge of 415 Capital and Brian R. Smith of S3 Ventures to its board of directors.
The Hēlo Thrombectomy System represents a breakthrough in clot removal technology, thanks to a patented dual-action mechanism that integrates powerful suction with advanced mechanical clot disruption. The system delivers high throughput performance through a small profile catheter, enabling efficient single-pass procedures. The Hēlo catheter is part of a complete system that incorporates further innovations to improve patient care, clinician experience and procedure efficiency. The Hēlo PE thrombectomy system for pulmonary embolism is for experimental use only and is not approved for commercial use; it is not currently available for sale. (photo: E2 website)
ALL RIGHTS RESERVED ©